Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ALTA-2618 by Alterome Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
ALTA-2618 is under clinical development by Alterome Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
Data Insights
ALTA-2618 by Alterome Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
ALTA-2618 is under clinical development by Alterome Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...